Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald P Radich

Showing results (131-140 of 208) with videos related to

Pageof 21
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Leukemia & Lymphoma|November 6, 2012
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms WorkshopRichard A Van Etten, Michael Mauro, Jerald P Radich, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemiaVivian G Oehler, Jerald P Radich, Barry Storer, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemiaFrédéric Baron, Michael B Maris, Barry E Storer, et al.
Blood|June 21, 2003
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistanceChristian M Zwaan, Soheil Meshinchi, Jerald P Radich, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Hematological Oncology|April 24, 2019
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasmsTariq I Mughal, Naveen Pemmaraju, Jerald P Radich, et al.
Pageof 21

Showing results (131-140 of 208) with videos related to

Sort By:
Pageof 21
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Leukemia & Lymphoma|November 6, 2012
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms WorkshopRichard A Van Etten, Michael Mauro, Jerald P Radich, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemiaVivian G Oehler, Jerald P Radich, Barry Storer, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemiaFrédéric Baron, Michael B Maris, Barry E Storer, et al.
Blood|June 21, 2003
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistanceChristian M Zwaan, Soheil Meshinchi, Jerald P Radich, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Hematological Oncology|April 24, 2019
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasmsTariq I Mughal, Naveen Pemmaraju, Jerald P Radich, et al.
Pageof 21